ARCHIVES

FDA Approves Gemzar For Ovarian Cancer, Contradicting ODAC Recommendation; Continues Agency Trend to Recognize Progression-Free Survival As An Endpoint.

This article is from The Cancer Letter archive.

Vol. 32 No. 28 | July 21, 2006

Download PDF Visit The Full Archive

Related Articles

For Research Projects In Cancer Therapy

March 1, 1996

FY2000 Appropriations: NIH Gets $17.9 Billion, A 15% Increase, In Final Budget Agreement; $3 billion to Be Delayed

November 26, 1999

ORI Whistle-Blower Proposal Too Rigid, Biologists Say.

February 2, 2001

Breast Cancer Rates Decline Most for Affluent White Women

February 26, 2010

Panel To Look At Cancer Centers Program, Starting With West Coast, Hawaii Meetings This Year, Next

January 27, 1984

The Antineoplaston Anomaly: How A Drug Was Used For Decades In Thousands Of Patients, With No Safety, Efficacy Data

September 25, 1998